On November 16, the President of the Russian Federation, Vladimir Putin, visited a new GEROPHARM factory manufacturing insulin substances in St. Petersburg ad held a meeting regarding improvement of system of medicine provision.
In the course of the visit V.V. Putin got a tour around the GEROPHARM factory where new technological lines to produce insulin substances were presented. After launching the projected capacity the factory will be able to produce 1,000 kg of the substance per year which makes it possible to meet 100 % of he population needs in insulin products and to develop export area. The uniqueness of the project is a full independence of the technological production process on import raw material deliveries.
“Recently the Russian pharmaceutical industry has taken a qualitative leap forward in development – today we can create modern highly technological production sites with maximum local content that not only solve tasks concerning import substitution but can also be competitive at the global level. We are actively expanding production and developing the drug line to treat diabetes in order to provide patients with high-quality Russian medicinal products”, GEROPHARM CEO, Pyotr Rodionov said.
The total area of the production complex is 11,000 m2. Production complies with GMP standards, 90 % of the processes are fully automated. While designing the factory, the modern technological decisions and the best world experience in establishment of pharmaceutical production sites in compliance with a high level of industrial and ecological safety were used.
The total volume of investment in construction of the factory amounted to 3.3 billion rubles. The project has been implemented with its own expensed and borrowed funds (Fund of Industrial Development, VTB) as well as within the program of the Russian Direct Investment Fund “Investment Lift”focused on development of highly technological projects associated with exports unrelated to raw materials.
The GEROPHARM factory is constructed within the framework of a special investment contract signed by the Ministry of Industry and Trade of the Russian Federation and St. Petersburg Government in December 2017. The project of special investment contracts provides for exploration and creation of medicinal products not having analogues in terms of local content within the Russian Federation, as well as provides for import substitution of socially important medicinal products – insulin and insulin analogues to treat diabetes.
The new factory will produce a line of insulin analogues – Insulin Lispro, Biphasic Insulin Lispro, Insulin Glargine, Aspart, Biphasic Insulin Aspart, Insulin Degludec that undergo different stages of studying at the moment. The medicinal products are developed within the framework of PHARMA-2020 program. The drugs are expected to be launched at the market in 2019–2021.
Diabetes was diagnosed in 4.7 million people in Russia. According to the Russian Healthcare Ministry this number increased by 40 % in comparison with 2010. According to some big epidemiologic studies about 50 % of Russians with diabetes do not know they are sick. So according to the estimate of specialists about 8–9 million of Russians suffer from diabetes. Apart from that, 20 % of Russians are now living through pre-diabetes stage.